

## LIDDS presents at high-profile event in connection with Nobel Prize festivities

**UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company is selected by special invite to present at the prestigious Science4Peace Event in Stockholm December 11-12, in connection with the Nobel Prize festivities.**

LIDDS' CEO, Anders Månsson, will present the company at the Science4Peace Event in Stockholm 11-12 December in connection with the Nobel Prize festivities. The event will feature leading members of the international science and investment communities, as well as top level government officials representing Sweden and the USA. For information about the event, see [www.science4peace.se](http://www.science4peace.se)

**For additional information, please contact**

---

Anders Månsson, CEO  
Phone: +46 (0)70 860 47 38  
E-mail: [anders.mansson@liddspharma.com](mailto:anders.mansson@liddspharma.com)

Jenni Björnulfson, CFO  
Phone: +46 (0)70 855 38 05  
E-mail: [jenni.bjornulfson@liddspharma.com](mailto:jenni.bjornulfson@liddspharma.com)

LIDDS' Certified Adviser is Redeye AB

**LIDDS in brief:**

---

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.